Johnson & Johnson (FRA:JNJ) 3-Year EBITDA Growth Rate : 0.50% (As of Dec. 2023)

View and export this data going back to 1944. Start your Free Trial

What is Johnson & Johnson 3-Year EBITDA Growth Rate?

Johnson & Johnson's EBITDA per Share for the three months ended in Dec. 2023 was €2.57.

During the past 12 months, Johnson & Johnson's average EBITDA Per Share Growth Rate was -8.80% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 0.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 0.40% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 2.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Johnson & Johnson was 20.10% per year. The lowest was -6.60% per year. And the median was 9.70% per year.

Competitive Comparison of Johnson & Johnson's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - General subindustry, Johnson & Johnson's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Johnson & Johnson's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Johnson & Johnson's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Johnson & Johnson's 3-Year EBITDA Growth Rate falls into.

Johnson & Johnson 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Johnson & Johnson (FRA:JNJ) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Johnson & Johnson 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Johnson & Johnson's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Johnson & Johnson (FRA:JNJ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Johnson & Johnson (FRA:JNJ) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

JNJ:USA JNJ:Peru JNJ:Mexico JNJ_KZ:Kazakhstan 1JNJ:Italy JNJd:UK 0R34:UK JNJ:Germany JNJ:Canada JNJB34:Brazil JNJ:Austria JNJ:Argentina

Address

One Johnson and Johnson Plaza, New Brunswick, NJ, USA, 08933

Website

https://www.jnj.com

Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.